Default company panoramic image
Logo

TheraSyn

Announcing the investor offering for MetaBrake LLC, Placing the first TheraSyn product into clinical development.

  • Stage Product In Development
  • Industry Other
  • Location Buffalo, NY, USA
  • Currency USD
  • Founded July 2007
  • Employees 3

Company Summary

TheraSyn Pharmaceuticals, Inc is an emerging clinical developer of both novel and improved oral medications for treatment of Type 2 Diabetes (T2D) and obesity. The product(s) being developed, Brake™ is the only known oral medication to mimic the curative Roux-en-Y gastric bypass (RYGB) surgical procedure. Our first product is a combination of Brake™ and Metformin, called MetaBrake™

Team

  • Default avatar
    Jerome J. Schentag
    Chairman, Managing Partner

    Professor of Pharmaceutical Sciences at University of Buffalo, founder of TheraSyn (2007) and MetaBrake LLC (2012)

  • Default avatar
    Felix Botelho, MBA
    CEO

    30 years of business development experience include Merck both domestically and internationally. Founded several companies with exit as sale to large pharma

  • Default avatar
    Paul Barone
    CFO

    20 years experience in large pharmaceutical management

Advisors

  • Default avatar
    DLA Piper LLP
    Lawyer
    Unconfirmed
    Default avatar
    Schunk Wilson PC
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    University at Buffalo has an equity position
    Unconfirmed